Community Pharmacy Expert Advisory Group

Experts in Community Pharmacy

Providing strong representation for community pharmacy, our Community Pharmacy Expert Advisory Group (CPEAG) ensures this area of practice is both recognised and supported across England, Scotland and Wales.

The Community Pharmacy EAG acts as a source of expertise, advice and opinion to inform RPS policy decisions and work plans.

An empowered and representative network of experts across all relevant backgrounds, the group identifies the needs of community pharmacy in relation to:

  • Professional development
  • Practice support
  • Advocacy. 

CPEAG review of 2022

Throughout 2022 we've represented community pharmacy across England, Scotland and Wales, responding to consultations, helping the boards to shape policy, and advocating for RPS.

Here are some of the highlights:

  • Vision for pharmacy professional practice
    + EXPAND

    This year has seen exciting developments from the RPS in the three country specific visions. In December, as part of a commissioned piece of work between RPS and the Kings Fund, a vision for Pharmacy professional practice in England was launched.

    RPS Wales held a launch event of interim 2025 goals in October, following on from its vision for the profession, launched in 2019, “Pharmacy: Delivering a Healthier Wales”.

    Pharmacy 2030: a vision for community pharmacy in Scotland was launched in March to help shape the future of the community pharmacy setting.

    Always maintaining the patient at the core of recommendations, input from the group was key to helping shape the documents, whilst remaining pertinent to the challenges experienced in the sector. The CPEAG provided information, ideas and challenge and are excited to see how the visions develop over the coming years and will be vital in helping to implement these in community pharmacy.

  • Strengthening pharmacy governance
    + EXPAND

    CPEAG had several sessions informing RPS’ approach to challenges such as supervision in community pharmacy and how the introduction of hub and spoke can affect practice. The group want to ensure progressive, safe, and effective pharmacy services within a modern and advancing NHS, whilst maintaining protection for the public.

    The group will continue to discuss key topics and consider how RPS can support members to embrace digital changes and enhanced skill mix, to allow pharmacists time to deliver more clinical services for the benefits of patients.

  • Expanding Scope of practice for Independent prescribers
    + EXPAND

    The CPEAG helped to inform the development of this important guidance. The guidance provides a structure to support prescribers to identify their developmental needs, highlights ways in which these needs can be met, and offers guidance on how to document the process and outcomes. Following discussion, the group offered comments and suggestions to help ensure the guidance was applicable to community pharmacists. The importance of de-prescribing plus the governance and risk management to deliver a safe and effective service was highlighted alongside the need to develop case studies and align this work to the current CPD cycle to avoid duplication of workload.

  • Marie Curie Daffodil standards for community pharmacy
    + EXPAND

    CPEAG have made this a standing item on the agenda to ensure the project team gain insights from the breadth of expertise we have on the group. This has included shaping the core standards and advising on the activities that are currently undertaken and those that we should seek to include and giving feedback on the resources that might be useful to support implementation of the standards.

  • Good Clinical Governance in Community Pharmacy
    + EXPAND

    The CPEAG have engaged throughout the year with the GPhC, feeding into the GPhC Clinical Governance pilot themed review at various stages. Through helping shape what good clinical governance looks like in community pharmacies to describing real life examples, CPEAG have been a key stakeholder to help guide the review. The CPEAG looks forward to seeing the preliminary outcomes of the review, how this will shape future regulatory visits and is excited to contribute to further development in this area for the benefit of the sector and patient safety alike.

  • Summary and Next Steps

    The CPEAG have contributed significantly to the development of RPS guidance and the shaping of policy and consultation responses relevant to community pharmacy during 2022. Thank you to all the group members for their contributions to date. We look forward to continuing to support the RPS team and boards on key issues affecting community pharmacy in 2023.

CPEAG Meetings




Chair: Janice Perkins

  • Sobia Janjua
  • Sarah Passmore
  • Jonathan Smith
  • Gary Evans
  • Amber Manoiu
  • Waqas Ahmad
  • Jonathan James
  • Aron Berry
  • Mohammed Ibrahim
  • Paul Jenks
  • Patricia Tigenoah - Ojo
  • Nick Thayer
  • Vivyana Matanda
  • Stacey Anderson
  • Diane Robertson

Contact CPEAG

[email protected]

Terms of reference